| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
|
| ln Vitro |
The main target of serine hydrolase, hMAGL, is MJN110 (0.01-1000 nM; 4 hours); its IC50 is about 1 nM, and its selectivity window is 10- and 100-fold greater than that of ABHD6 and LYPLA1/2, respectively [2].
|
|---|---|
| ln Vivo |
In a dose-dependent manner, MJN110 (ip; 0.0818 mg/kg; twice daily for 5.5 days) reverses the effects of chronic constriction injury (CCI) on mechanical allodynia and thermal hyperalgesia. 0.430 (0.233-0.793) mg/kg is the comparable ED50 value (95% confidence limit)[1].
|
| Cell Assay |
Western blot analysis[2]
Cell Types: Human PC3 cells Tested Concentrations: 0.01, 0.1, 1, 10, 100, 1000 nM Incubation Duration: 4 hrs (hours) Experimental Results: HMAGL acts as a major serine hydrolase target with an IC50 of approximately 1 nM. |
| Animal Protocol |
Animal/Disease Models: Male C57BL/6J mice, body weight range 18 to 35 g[1]
Doses: 0.0818 mg/kg Route of Administration: intraperitoneal (ip) injection; twice (two times) daily for 5.5 days Experimental Results: Reversal of CCI-induced disease in a dose-dependent manner of mechanical allodynia and thermal hyperalgesia. |
| References |
|
| Additional Infomation |
MJN110 is a diarylmethane.
|
| Molecular Formula |
C22H21CL2N3O4
|
|---|---|
| Molecular Weight |
462.327
|
| Exact Mass |
461.091
|
| CAS # |
1438416-21-7
|
| PubChem CID |
71722059
|
| Appearance |
White to off-white solid powder
|
| Density |
1.47±0.1 g/cm3
|
| Boiling Point |
561.5±60.0 °C
|
| LogP |
3.714
|
| Hydrogen Bond Donor Count |
0
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
31
|
| Complexity |
632
|
| Defined Atom Stereocenter Count |
0
|
| InChi Key |
BEADRWVIFHOSGN-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C22H21Cl2N3O4/c23-17-5-1-15(2-6-17)21(16-3-7-18(24)8-4-16)25-11-13-26(14-12-25)22(30)31-27-19(28)9-10-20(27)29/h1-8,21H,9-14H2
|
| Chemical Name |
(2,5-dioxopyrrolidin-1-yl) 4-[bis(4-chlorophenyl)methyl]piperazine-1-carboxylate
|
| Synonyms |
MJN110; MJN 110; MJN-110
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~540.74 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.50 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.50 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 2.08 mg/mL (4.50 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1630 mL | 10.8148 mL | 21.6296 mL | |
| 5 mM | 0.4326 mL | 2.1630 mL | 4.3259 mL | |
| 10 mM | 0.2163 mL | 1.0815 mL | 2.1630 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
